Ms. Lucia joined Saxon Securities in 2010, and has over 20 years of experience in finance and accounting.

Ms. Lucia's experience includes her role as CFO at Prospect Venture Partners, a venture capital firm with over $1 billion in committed capital, and as CFO at Asset Management Ventures where she was responsible for accounting, finance and investor relations. Previously, she was Director of Finance at CV Therapeutics ("CVT") until the acquisition of the company by Gilead Sciences in 2009 for $1.4B. Ms. Lucia was also CFO at Care and Health in London, UK. Previously, Ms. Lucia was Director of Investor Relations at Chiron Corporation until its acquisition by Novartis in 2006 at a value of $8.8B. She began her career at Deloitte where she progressed through various positions in audit and financial consulting, most recently as a Senior Manager in the Financial Advisory Services group.

Ms. Lucia earned her MBA from Kellogg School of Management, a Chartered Financial Analyst designation, and in 1997 she earned a Canadian Chartered Accountant designation (not active).